Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis
Pirfenidone (Esbriet®) is an orally administered, synthetic, pyridone compound that is approved for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU, and for the treatment of IPF in the USA. This article summarizes pharmacological, efficacy and tolerability data relevant to the use of pirfenidone in these indications. In the randomized, double-blind, placebo-controlled, multinational CAPACITY trials in patients with mild to moderate IPF, a significant reduction in the rate of decline in forced vital capacity (FVC) was seen with pirfenidone versus placebo in study 004 but not in study 006. Pirfenidone also reduced the rate of decline in FVC to a significantly greater extent than placebo in the randomized, double-blind, multinational ASCEND trial in this patient population. In addition, pirfenidone showed a significant treatment effect on the 6-min walking test distance and progression-free survival in the ASCEND trial and in a pooled analysis of the CAPACITY trials. Pirfenidone had a manageable tolerability profile in all three studies. Gastrointestinal and skin-related events (e.g. nausea, rash, photosensitivity reaction), which were the most commonly occurring treatment-emergent adverse events, were generally mild to moderate in severity. In addition, a prespecified mortality analysis across all three studies demonstrated a significant reduction in IPF-related and all-cause mortality with pirfenidone. In conclusion, oral pirfenidone is a valuable agent for use in patients with IPF.
KeywordsIdiopathic Pulmonary Fibrosis Forced Vital Capacity Usual Interstitial Pneumonia Idiopathic Pulmonary Fibrosis Patient Pirfenidone
The preparation of this review was not supported by any external funding. Esther S. Kim and Gillian M. Keating are salaried employees of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.
- 4.European Respiratory Society. Interstitial lung diseases. In: Gibson GJ, Loddenkemper R, Sibille Y, Lundbäck B, editors. European lung white book: respiratory health and disease in Europe. Sheffield: European Respiratory Society; 2013. p. 256–69.Google Scholar
- 6.Sandbo N. Mechanisms of fibrosis in IPF. In: Meyer KC, Nathan SD, editors. Idiopathic pulmonary fibrosis: a comprehensive clinical guide. New York: Humana Press; 2014. p. 161–205.Google Scholar
- 11.European Medicines Agency. Esbriet (pirfenidone) hard capsules: EU summary of product characteristics. 2014. http://www.ema.europa.eu. Accessed 5 Jan 2015.
- 12.US FDA. Esbriet (pirfenidone) capsules: US prescribing information. 2014. http://www.accessdata.fda.gov. Accessed 5 Jan 2015.
- 13.US FDA. Two FDA drug approvals for idiopathic pulmonary fibrosis (IPF). 2014. http://blogs.fda.gov. Accessed 20 Oct 2014.
- 19.Hostettler K, Zhong J, Tamm M, et al. Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis [abstract no. P763]. In: ERS international congress; 2014.Google Scholar
- 20.European Medicines Agency. Esbriet (pirfenidone): CHMP assessment report. 2011. http://www.ema.europa.eu. Accessed 21 Oct 2014.
- 23.He X, Long X, Wessendorf TE, et al. Pirfenidone suppresses proinflammatory and antiangiogenetic cytokine production by alveolar macrophages (AMs) in idiopathic non specific interstitial pneumonia (iNSIP) [abstract no. P764]. In: ERS international congress; 2014.Google Scholar
- 34.InterMune. InterMune reports phase 3 ASCEND trial results of pirfenidone in idiopathic pulmonary fibrosis (IPF) [media release], 25 Feb 2014. http://www.intermune.co.uk.
- 35.US National Institutes of Health. ClinicalTrials.gov. 2015. http://clinicaltrials.gov. Accessed 5 Jan.
- 37.Kohlhaeufl MJ, Ingerl H, Bachnik M. Pirfenidone in idiopathic pulmonary fibrosis—description of a German cohort [abstract no. P3749]. In: ERS international congress; 2014.Google Scholar
- 38.MacQuarrie JL, Lebel F. Pirfenidone use in clinical practice: analysis of data from a Canadian patient support program for patients with idiopathic pulmonary fibrosis (INSPIRATION) [abstract no. A1428]. Am J Respir Crit Care Med. 2014;189(Meeting abstracts).Google Scholar
- 39.Nieto A, Valenzuela C, Rivera I, et al. Pirfenidone in idiopathic pulmonary fibrosis (ipf): Spanish experience with the European named patient program (npp) and Spanish patient progam (spp) [abstract no. A1418]. Am J Respir Crit Care Med. 2014;189 (Meeting abstracts).Google Scholar
- 40.Loeh B, Drakopanagiotakis F, Bandelli GP, et al. Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts [abstract no. 854923]. In: ERS international congress; 2014.Google Scholar
- 41.Wijsenbeek MS, Van Beek FT, Geel AL, et al. Pirfenidone in daily clinical use in patients with idiopathic pulmonary fibrosis in the Netherlands [abstract no. A4340]. Am J Respir Crit Care Med. 2013;187(Meeting abstracts).Google Scholar
- 45.Ravaglia C, Gurioli C, Romagnoli M, et al. Pirfenidone treatment in idiopathic pulmonary fibrosis: an Italian case series [abstract no. P3370]. Eur Respir J. 2013;42(Suppl. 57):688s.Google Scholar
- 46.Nathan SD, Albera C, Bradford WZ, et al. Long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): integrated analysis of data from 4 clinical trials [abstract no. A1422]. Am J Respir Crit Care Med. 2014;189(Meeting abstracts).Google Scholar
- 47.Koschel D, Cottin V, Sköld M, et al. Pirfenidone post-authorization safety registry (PASSPORT)—interim analysis of IPF treatment [abstract no. 850348]. In: ERS international congress; 2014.Google Scholar
- 48.Passport Study. PASSPORT: post-authorisation safety study of Esbriet (pirfenidone): a prospective observational registry to evaluate long-term safety in a real-world setting. 2014. www.passportstudy.com. Accessed 21 Aug 2014.
- 55.US FDA. FDA approves Esbriet to treat idiopathic pulmonary fibrosis [media release], 15 Oct 2014. http://www.fda.gov.
- 56.National Institute for Health and Care Excellence. Pirfenidone for treating idiopathic pulmonary fibrosis. 2013. http://www.nice.org.uk. Accessed 3 Sep 2014.
- 57.Swedish Respiratory Society. Vårdprogram för idiopatisk lungfibros [in Swedish]. 2012. http://www.slmf.se. Accessed 4 Sep 2014.
- 59.National Centre for Pharmacoeconomics Ireland. Cost-effectiveness of pirfenidone (Esbriet®) for the treatment of idiopathic pulmonary fibrosis. 2013. http://www.ncpe.ie. Accessed 4 Sep 2014.
- 60.National Institute for Health and Care Excellence. Pirfenidone for treating idiopathic pulmonary fibrosis: overview and resources. 2013. http://www.nice.org.uk. Accessed 3 Sep 2014.
- 61.Scottish Medicines Consortium. SMC advice for drugs accepted with a PAS: pirfenidone. 2013. http://www.scottishmedicines.org.uk. Accessed 9 Oct 2014.
- 62.PR Newswire. France’s economic committee (CEPS) authorizes reimbursement of Esbriet® (pirfenidone) [media release], 11 Sep 2012. http://www.prnewswire.com.
- 63.PR Newswire. InterMune announces publication of pricing and reimbursement conditions for Esbriet® (pirfenidone) in Italy [media release], 14 Jun 2013. http://www.prnewswire.com.
- 64.InterMune. A randomized, double-blind, placebo-controlled, phase 2 study of the safety and tolerability of N-acetylcysteine in patients with idiopathic pulmonary fibrosis with background treatment of pirfenidone [Clinicaltrialsregister.eu identifier 2012-000564-14] European Medicines Agency, Clinicaltrialsregister.eu. 2013. https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000564-14/DE. Accessed 10 Oct 2014.